Department of Geriatrics & Endocrinology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, China.
Acta Pharmacol Sin. 2019 May;40(5):648-657. doi: 10.1038/s41401-018-0109-4. Epub 2018 Aug 8.
Hyperglycemia is a major factor in vascular endothelial injury that finally leads to a cardiovascular event. Steroid receptor coactivators (SRCs) are a group of non-DNA binding proteins that induce structural changes in steroid receptors (nuclear receptors) critical for transcriptional activation. SRCs, namely, SRC-1, SRC-2, and SRC-3, are implicated in the regulation of vascular homeostasis. In this study we investigate the role of SRCs in hyperglycemia-induced endothelial injury. Aortic endothelial cells were prepared from normal and diabetic rats, respectively. Diabetic rats were prepared by injection of streptozotocin (50 mg/kg, i.p.). The expression levels of SRC-1 and SRC-3 were significantly decreased in endothelial cells from the diabetic rats. Similar phenomenon was also observed in aortic endothelial cells from the normal rats treated with a high glucose (25 mM) for 4 h or 8 h. The expression levels of SRC-2 were little affected by hyperglycemia. Overexpression of SRC-1 and SRC-3 in high glucose-treated endothelial cells significantly increased the cell viability, suspended cell senescence, and inhibited cell apoptosis compared with the control cells. We further showed that overexpression of SRC-1 and SRC-3 markedly suppressed endothelial injury through restoring nitric oxide production, upregulating the expression of antioxidant enzymes (SOD, GPX, and CAT), and activating the PI3K/Akt pathway. The beneficial effects of SRC-1 and SRC-3 overexpression were blocked by treatment with the PI3K inhibitor LY294002 (10 mM) or with the Akt inhibitor MK-2206 (100 nM). In conclusion, hyperglycemia decreased SRC-1 and SRC-3 expression levels in rat aortic endothelial cells. SRC-1 and SRC-3 overexpression might protect against endothelial injury via inhibition of oxidative stress and activation of PI3K/Akt pathway.
高血糖是血管内皮损伤的一个主要因素,最终导致心血管事件。类固醇受体共激活剂(SRCs)是一组非 DNA 结合蛋白,可诱导对转录激活至关重要的类固醇受体(核受体)的结构变化。SRCs,即 SRC-1、SRC-2 和 SRC-3,与血管稳态的调节有关。在这项研究中,我们研究了 SRCs 在高血糖诱导的内皮损伤中的作用。分别从正常和糖尿病大鼠中制备主动脉内皮细胞。糖尿病大鼠通过链脲佐菌素(50mg/kg,ip)注射制备。糖尿病大鼠的内皮细胞中 SRC-1 和 SRC-3 的表达水平明显降低。在正常大鼠的主动脉内皮细胞中也观察到类似的现象,这些细胞用 25mM 的高葡萄糖处理 4 小时或 8 小时。SRC-2 的表达水平受高血糖影响较小。与对照细胞相比,在高葡萄糖处理的内皮细胞中过表达 SRC-1 和 SRC-3 可显著提高细胞活力、悬浮细胞衰老和抑制细胞凋亡。我们进一步表明,SRC-1 和 SRC-3 的过表达通过恢复一氧化氮产生、上调抗氧化酶(SOD、GPX 和 CAT)的表达以及激活 PI3K/Akt 通路来显著抑制内皮损伤。用 PI3K 抑制剂 LY294002(10mM)或 Akt 抑制剂 MK-2206(100nM)处理可阻断 SRC-1 和 SRC-3 过表达的有益作用。总之,高血糖降低了大鼠主动脉内皮细胞中 SRC-1 和 SRC-3 的表达水平。SRC-1 和 SRC-3 的过表达可能通过抑制氧化应激和激活 PI3K/Akt 通路来保护内皮免受损伤。